Menetelmä farmaseuttisesti vaikuttavien triatsolopyridatsiiniyhdisteiden valmistamiseksi

摘要

Novel compound represented by the formula: wherein R<1> stands for H, an optionally substituted lower alkyl group or a halogen; R<2> and R<3> respectively stands for a hydrogen or an optionally substituted lower alkyl group, or R<2> and R<3> may, taken together with the adjacent -C=C- group, form a 5- to 7-membered ring; X stands for O, SO or SO2; Y stands for a group of the formula: (R<4> and R<5> respectively stand for H or an optionally substituted lower alkyl group) or a divalent group derived from an optionally substituted 3- to 7-membered homocyclic or heterocyclic ring; R<6> and R<7> each stands for H, an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group or an optionally substituted aryl group, or R<6> and R<7> may, taken together with the adjacent N, form an optionally substituted N-containing heterocyclic group; m stands for 0 to 4; n stands for 0 to 4, or a salt thereof, which has excellent anti-PAF activities anti-LTC4 activities and anti-ET-1 activities, and is of value as an antiasthmatic agent, and their production, intermediates and pharmasceutical compositions.